Health organisations remain concerned about issues such as regulatory data protection and innovation incentives, following the European Parliament’s Public Health Committee’s (ENVI) compromise on the revision of the EU pharmaceutical legislation.
ENVI members voted on Tuesday (19 March) in favour of common positions on the directive and regulation comprising the revision of the EU’s pharmaceutical legislation. Health organisations…